论文部分内容阅读
慢性气管炎是一种常见的呼吸道疾病,在世界范围内发病率和死亡率都比较高,可是到目前为止,尚无特效的根治疗法,药物治疗措施大都停留在对症治疗水平上,对症治疗虽然对减少病人的痛苦,控制疾病的发展和急性发作有一定的意义,但是,不能达到根治的目的。对症治疗药物包括抗感染、平喘、镇咳、祛疾等四个方面,而感冒和流感往往又是慢性气管炎的发病和加重的主要原因,因此,防治感冒和流感对治疗慢性气管炎具有一定的重要意义。据不完全统计,国外常用的和将要上市的原料药品种约106种,(磺胺、抗菌素未统计在内),我国投产的品种约50种,(包括国内创制新药7种,疗效好的中草药5种)。据日本厚生省统计,1982年日本呼吸器官药物的产值为90,558百万日元,约
Chronic bronchitis is a common respiratory disease, the incidence and mortality in the world are relatively high, but so far there is no effective radical therapy, most of the drug treatment measures remain symptomatic treatment, although symptomatic treatment To reduce the suffering of patients, control the development of the disease and acute exacerbations have some significance, however, can not achieve the purpose of cure. Symptomatic treatment of drugs, including anti-infective, asthma, antitussive, disability and other four areas, and flu and flu are often the main cause of chronic bronchitis and aggravate the disease, therefore, the prevention and treatment of colds and flu for chronic bronchitis have A certain significance. According to incomplete statistics, there are about 106 kinds of APIs commonly used in the world and to be listed on the market (sulfonamides and antibiotics are not included), about 50 varieties are put into operation in our country (including 7 kinds of new medicines in China and 5 Chinese herbal medicines with good curative effect Species). According to the Japanese Ministry of Health, statistics, in 1982 the Japanese respiratory medicine output value of 90,558 million yen, about